Orthopedic Regenerative Surgical Products Market Size To Reach $5.63 Billion By 2030

Orthopedic Regenerative Surgical Products Market Growth & Trends

The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.63 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at an attractive CAGR of 4.0% from 2023 to 2030. The primary factors boosting the market growth include the growing older population, easy availability of orthopedic treatments & procedures, and technological advancements. For instance, osteoarthritis, an orthopedic ailment, has been considered the major factor of chronic disability in the geriatric population (aged above 70 years). The product demand was reduced during the COVID-19 pandemic owing to the low volume of patient flow for chronic ailments in hospitals & clinics, abated marketing & sales activities, postponed elective surgeries, social distancing, and lockdown protocols.

For example, Anika Therapeutics notified challenges in patient enrollment for its clinical trials owing to the pandemic, which adversely impacted the company’s operating results and revenue. However, the company recovered financial performance and operations as elective surgeries restarted post-pandemic. As per the Centers for Disease Control and Prevention (CDC), approximately 78 million adults in the U.S., or 26% of the population, are projected to be diagnosed with arthritis by 2040. The risk of arthritis increases with age and is found to be more common in females. Another risk factor is obesity. According to the CDC, the prevalence of obesity in the U.S. was estimated to be around 42.4% from 2017 to 2018. Thus, the growing prevalence of orthopedic ailments and the rising aging population & obesity cases are expected to drive market growth. The products used in orthopedic regenerative surgery have a wide range of applications, including gout, joint pain, fibromyalgia, articular defects, osteoarthritis, joint replacement, and trauma.

This is also anticipated to contribute to the growth of the market. Key players in the market are involved in several strategic initiatives, including R&D projects to introduce new regenerative solutions for pain relief from diseases. For instance, in March 2021, Amniox Medical, Inc., received FDA clearance to proceed with a dosing study using its Investigational New Drug (IND) TTAX03- consisting of the umbilical cord and cryopreserved amniotic membrane, to alleviate facet joint osteoarthritis pain. The market participants offer a wide range of orthopedic products; for instance, Zimmer Biomet provides a wide portfolio of synthetic orthopedic regenerative products and allografts, such as the InterGro DBM, PrimaGen Advanced allograft, and PlatFORM bioresorbable bone graft substitute.

 Request a free sample copy or view report summary: Orthopedic Regenerative Surgical Products Market Report

Orthopedic Regenerative Surgical Products Market Report Highlights

• The viscosupplements segment held the largest market share of about 42.59% in 2022 owing to the high prevalence of orthopedic conditions, such as osteoarthritis, and increasing product availability in the market

• The allografts segment is anticipated to witness a CAGR of 4.1% during the forecast period owing to the increasing utilization of allografts

• The joint reconstruction segment held the largest revenue share of 35.66% in 2022 in the application segment due to the rising adoption of regenerative solutions in joint reconstruction

• The cartilage & tendon repair segment is estimated to grow at the fastest CAGR of 4.2% during the forecast period owing to increasing applications in geriatric patients and sports medicine

• The hospital end-use segment dominated the market and held the largest revenue share of about 49.04% in 2022 as most orthopedic treatments are performed in hospital settings

• The ambulatory surgical centers (ASCs) segment is expected to showcase the fastest CAGR of 4.1% during the forecast period

• Key players in the market are undertaking various strategic initiatives, including product development & launches, R&D, regional expansion, and distribution network expansion

• In January 2021, Stryker acquired OrthoSensor, Inc., a private company that specializes in sensor technology and musculoskeletal care

Orthopedic Regenerative Surgical Products Market Segmentation

Grand View Research has segmented the global orthopedic regenerative surgical products market based on product, application, end-use, and region:

Orthopedic Regenerative Surgical Products Outlook (Revenue, USD Billion, 2018 - 2030)

• Allografts

  • Amniotic Products

  • Others

• Synthetic

• Cell-based

• Viscosupplements

Orthopedic Regenerative Surgical Products Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Orthopedic Pain Management

• Trauma Repair

• Cartilage & Tendon Repair

• Joint Reconstruction

• Others

Orthopedic Regenerative Surgical Products End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers

• Others

Orthopedic Regenerative Surgical Products Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

List of Key Players in the Orthopedic Regenerative Surgical Products Market

• Vericel Corporation

• Anika Therapeutics, Inc.

• Zimmer Biomet

• Baxter

• Stryker

• AlloSource

• Smith+Nephew

• Amniox Medical, Inc.

• Aptissen S.A

• VSY Biotechnology

• MiMedx